Skip to content

Enliven Therapeutics

US · ELVN #2416 by market cap Listed 1970
46.53 +0.12 +0.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About Enliven Therapeutics

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Founded
2019
CEO
Mr. Richard A. Fair
Employees
60
Headquarters
Burlingame, California, United States of America
Fiscal year end
12-31
Website
enliventherapeutics.com

Company profile

Exchange
US
Symbol
ELVN
Market-cap rank
#2416
Listing date
1970-01-01
Market cap
3.42B
Float cap
3.02B
Shares out
73.60M
Float shares
64.84M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Enliven Therapeutics discussion 0 comments

Add a comment